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Glucagon-like peptide-1 (GLP-1) is protective in lung disease models but the underlying mechanisms 
remain elusive. Because the hormone atrial natriuretic peptide (ANP) also has beneficial effects in 
lung disease, we hypothesized that GLP-1 effects may be mediated by ANP expression. To study this 
putative link, we used a mouse model of chronic obstructive pulmonary disease (COPD) and assessed 
lung function by unrestrained whole-body plethysmography. In 1 study, we investigated the role of 
endogenous GLP-1 by genetic GLP-1 receptor (GLP-1R) knockout (KO) and pharmaceutical blockade 
of the GLP-1R with the antagonist exendin-9 to -39 (EX-9). In another study the effects of exogenous 
GLP-1 were assessed. Lastly, we investigated the bronchodilatory properties of ANP and a GLP-1R 
agonist on isolated bronchial sections from healthy and COPD mice.
Lung function did not differ between mice receiving phosphate-buffered saline (PBS) and EX-9 or 
between GLP-1R KO mice and their wild-type littermates. The COPD mice receiving GLP-1R agonist 
improved pulmonary function (P < .01) with less inflammation, but no less emphysema compared to 
PBS-treated mice. Compared with the PBS-treated mice, treatment with GLP-1 agonist increased 
ANP (nppa) gene expression by 10-fold (P < .01) and decreased endothelin-1 (P < .01), a peptide as-
sociated with bronchoconstriction. ANP had moderate bronchodilatory effects in isolated bronchial 
sections and GLP-1R agonist also showed bronchodilatory properties but less than ANP. Responses to 
both peptides were significantly increased in COPD mice (P < .05, P < .01).
Taken together, our study suggests a link between GLP-1 and ANP in COPD.
© Endocrine Society 2019.
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Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted from the small and large 
intestine on meal intake (1, 2). It potentiates glucose-stimulated insulin secretion from pan-
creatic β cells and is therefore recognized as an incretin hormone (3). Owing to its glycemic 
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and anorexic effects, GLP-1 receptor (GLP-1R) agonists are used for the treatment of type 2 
diabetes and obesity (4). GLP-1 also has extrapancreatic effects including regulation of vas-
cular tone and is thought to provide cardioprotection and neuroprotection (5-7). GLP-1 acts 
by binding to GLP-1R, which is found in the brain, heart, stomach, intestine, kidney, and 
nerves (6, 8-12). Additionally, several studies have shown the expression of GLP-1R in lung 
tissue (11, 13-18), which has motivated studies investigating a putative protective role of 
GLP-1 in lung disease in different rodent models (19-26). Viby et al showed that exogenous 
administration of the GLP-1R agonists liraglutide (lira) and exendin-4 (EX-4) improved 
lung function and reduced mortality in a mouse model of obstructive pulmonary disease 
(20). The improved lung function involved a decrease in enhanced pause (PenH), a measure 
of broncho-obstruction in mice, suggesting that GLP-1 might have bronchodilatory effects.
Interestingly, GLP-1 was recently linked to secretion of atrial natriuretic peptide (ANP) in 
a study published by Kim and colleagues. They demonstrated that GLP-1 reduced blood pres-
sure by stimulating the release of ANP (12). The main function of ANP is to lower blood pres-
sure by a number of actions in the kidney, where it increases vascular permeability, induces 
vasorelaxation, and causes natriuresis (27). Furthermore, ANP inhibits the production of 
aldosterone by actions in the adrenal glands and induces vasorelaxation of vascular smooth 
muscle cells in general (28-33). ANP may also be secreted from cells in the lung (33, 34) and 
some studies have shown a direct relaxant effect of ANP on isolated bronchi from guinea 
pigs and cows (35-37). A role of ANP in human lung diseases has also been investigated, and 
increased levels of ANP have been reported in adult respiratory distress syndrome (38) as 
well as in patients with chronic obstructive pulmonary disease (COPD) (39). Furthermore, in 
patients with asthma, ANP infusions have had bronchodilatory effects (40). Taken together, 
this suggests that ANP may exert direct beneficial effects on the bronchi that could improve 
lung function in disease states. Little is known, however, about the underlying mechanisms, 
including whether the actions of GLP-1 and ANP might be associated.
In the present studies, our major aim was to evaluate the potential effect of endogenous 
GLP-1 during pulmonary disease. We induced GLP-1 signaling deficiency by either blocking 
GLP-1R pharmaceutically (with EX-9) or by genetic deletion of the GLP-1R and subjected 
these animals to a mouse model of COPD (20). Our main end point was lung function, 
which was measured in a whole-body plethysmograph with PenH as a measurement of 
bronchoconstriction. In addition, we analyzed (by quantitative polymerase chain reaction 
[qPCR]) the expression of key candidate genes in lung disease, including nppa and ANP 
receptors (npr1 and npr3) in COPD mice treated with GLP-1R agonists. We also performed 
direct measurements of the bronchodilatory effects of ANP and GLP-1R agonists on isolated 
bronchi of healthy and COPD mice. Because of the reported anti-inflammatory effects of 
GLP-1 in the lung (41-43), we additionally investigated whether the protective effect of ex-
ogenous GLP-1R agonists could be mediated by attenuation of inflammation.
1.  Methods
A.  Animals
All experiments were conducted in accordance with internationally accepted principles 
for the care and use of laboratory animals, and the animal studies were approved by the 
Danish Animal Experiments Inspectorate (2013-15-2934-00833). Ten-week-old BALB/c and 
C57BL/6JRj female mice weighing approximately 20 g were obtained from Janvier Labs 
(Saint Berthevin).
Mice were housed in air-conditioned (21°C) and humidity-controlled (55%) rooms with a 
12-hour light, 12-hour dark cycle with free access to food and water.
The constitutive knockout (KO) mouse for GLP-1R (Glp1r KO) was generated deleting 
exons 4 and 5 of the Glp1r gene on Cre expression. We purchased the conditional KO for 
the Glp1r gene from the MRC Harwell Institute (C57BL/6N-Glp1rtm1c(KOMP)MbpH) (44). 
In this mouse, exons 4 and 5 are flanked by LoxP sites. This conditional model was bred 
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to cytomegalovirus-Cre (45), which expresses Cre recombinase ubiquitously, resulting in a 
constitutive KO allele for Glp1r (Glp1r (fl/fl) × Cre). All animals were bred by heterozygote 
crossing. The offspring were genotyped by PCR on genomic DNA extracted from ear snips 
using optimized primers (Table 1).
Wild-type (WT) littermates (Glp1r (+/+) × Cre) were used as control animals in all 
experiments. All genetically modified animals used in the experiments were female, 
10 ± 1-week-old, and generation N3 to N4.
Before experiments were initiated the strain was validated by showing lack of insulin 
secretion from the pancreatic β cells on stimulation with GLP-1 in the KO mice in an iso-
lated perfused pancreas preparation. We also validated the mice by the absence of GLP-1R 
antibody (ab) immune reactivity.
B.  Isolated Perfused Mouse Pancreas
Pancreas perfusions were performed as previously described (46). In short, the mice were 
anesthetized with intraperitoneal injection of ketamine (90  mg/kg Ketaminol vet, MSD 
Animal Health) and xylazine (10 mg/ml, Rompun vet, Bayer Animal Health).
The stomach, kidney, and spleen were tied off. Proximally to the celiac artery, the aorta 
was ligated, and a catheter was inserted in the aorta thereby providing arterial perfu-
sion with a modified Krebs-Ringer bicarbonate buffer (in mM: 118.3 NaCl, 3.0 KCL, 2.6 
CaCl2*2H2O, 1.2 KH2PO4, 1.2 MgSO*2H2O, 25.0 NaHCO3, 10 glucose, 0.1% bovine serum 
albumin, 5% dextran) (Pharmacosmos). Effluent samples were collected through a portal 
vein catheter every minute. The perfusion system (UP-100 universal perfusion system, 
Hugo Sachs Electronic) had a constant flow of 1 mL/min, perfusion buffer was maintained 
at 37°C, oxygenated with 95% O2 to 5% CO2, and perfusion pressure (40-50 mmHg) was 
monitored throughout the experiment. GLP-1R KO mice or WT littermates (n = 8) were 
stimulated for 10 minutes with 0.1 nM and 1.0 nM GLP-1 7-36 amide (Bachem) at 15 and 
40 minutes, respectively. At the end of the experiments, L-arginine was added as a positive 
control (10 mM).
Insulin concentrations in venous effluents were quantified by use of an in-house radioim-
munoassay, employing ab code 2006-3 (47, 48).
Table 1. Table of Primers Used for Genotyping and Gene Expression Analysis
Cre F GCC TGC ATT ACC GGT CGA TGC AAC GA
 R GTG GCA GAT GGC GCG GCA ACA CCA TT
Murine GLP-1r 5’arm WT F GGAGGATAGGACATAGTCCCAAA
Murine GLP-1r Crit WT R CCCAGCCACTCTCAGCTATT
Murine GLP-1r 5’mut R GAACTTCGGAATAGGAACTTCG
Murine GLP-1r 5’CAS F AAGGCGCATAACGATACCAC
 R CCGCCTACTGCGACTATAGAGA
Murine GLP-1r 3’LOXP R ACTGATGGCGAGCTCAGACC
ANP (nppa) F TGCCGGTAGAAGATGAGGTC
R AGCCCTCAGTTTGCTTTTCA
ANPR-A (nrp1) F AAGAGACGATGGGCAGGATA
R CACTGCCTGGACATAGAGCA
ANPR-C (npr3) F TGACACCATTCGGAGAATCA
R TTTCACGGTCCTCAGTAGGG
ET-1 (edn1) F CTGCCAAGCAGGAAAAGAAC
R TTGTGCGTCAACTTCTGGTC
Apelin (apl) F ATGAATCTGAGGCTCTGCGTGCAG
R TTAGAAAGGCATGGGGCCCTTATG
E-selectin (sele) F CGCCAGAACAACAATTCCAC
R ACTGGAGGCATTGTAGTACC
Hypoxanthine phosphoribosyltransferase 1 (hprt-1) F AAGCTTGCTGGTGAAAAGGA
R GGCTTTGTATTTGGCTTTTCC
Abbreviations: F, forward; R, reverse.
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C.  Mouse Model of Chronic Obstructive Pulmonary Disease
To induce development of a COPD-like phenotype, we used a model (20) that combines 
elements from an ovalbumin (OVA)-induced asthma model and a model of lipopolysac-
charide (LPS)-induced COPD (20). Mice were injected subcutaneously (s.c.) with 0.1 mL 
homogenized heat-coagulated hen’s egg white. After a 14-day sensitization period, the ani-
mals were subjected to aerosolized OVA (20 mg/mL; Sigma-Aldrich) on days 14 and 16 and 
aerosolized LPS from Escherichia coli O55:B55 (2.5 mg/mL; Lot No. 057M4013V, Sigma-
Aldrich) on days 15 and 17 in an exposure chamber (Buxco). In both cases, compounds were 
delivered at an air flow rate of 2 L/min for 30 minutes with OVA and 15 minutes with LPS.
D.  Determination of Lung Function
Lung function measurements were carried out using a whole-body plethysmograph (Emka 
Technologies) for unrestrained rodents. Bronchoconstriction was measured indirectly by 
PenH measurements, which is a calculated composite index indicative of airway obstruction 
based on changes in breathing patterns as a result of bronchoconstriction (49). PenH = PEP/
PIP × pause, (pause = Te–Tr/Tr), where PEP is the peak expiratory pressure, PIP is the peak 
inspiratory pressure, Te is the time of expiration, and Tr is the relaxation time, which is 
the time needed for the pressure decay to reach 36% of the total expiratory pressure signal. 
PenH values less than 1 are considered normal.
Animals were measured once daily from day  12. On day  18, the animals were meas-
ured at exactly 12, 14, and 16 hours after the last LPS inhalation. Data are presented as 
time-effect plots and as bar graphs showing PenH values at day 18, 12 hours after the last 
LPS inhalation. Statistics were carried out using 1-way analysis of variance (ANOVA) in 
GraphPad Prism version 7.
E.  Optimization of the Model
We first investigated the responsiveness to COPD induction in 2 widely used mouse strains: 
BALB/c and C57BL/6JRj with and without sensitization with an OVA pellet injected s.c. (50, 
51). Next, we investigated the duration of the response in C57BL/6JRj mice by exposing 1 
group of mice (n = 8) to LPS in the morning followed by measurements every 2 hours during 
the day, and the other group (n = 8) was exposed in the evening and evaluated the following 
day. PenH peaked 10 to 12 hours after the last LPS inhalation but after 30 hours PenH was 
less than 1. Based on this, we continued our experiments with C57BL/6JRj mice, which 
were either euthanized in the peak period at 12 hours (referred to as the “12-h” group in the 
remaining text) or 72 hours after last LPS inhalation (referred to as the “72-h” group from 
here on). Data from the optimization experiments are found in Fig. 1.
F.  Chronic Obstructive Pulmonary Disease Model
In the first experiment, 48 C57BL/6JRj mice were divided into 3 groups receiving lira, EX-9, 
or PBS. Plethysmograph measurements were performed for 3 minutes, and the animals 
were humanely killed 12 or 72 hours after last LPS inhalation.
In the next experiment, GLP-1R KO mice and WT littermates (n = 30) had COPD in-
duced and plethysmography was performed as above. Mice were humanely killed 12 or 
72 hours after last LPS inhalation.
For statistical analysis of differences in PenH between groups, 1-way ANOVA followed by 
Bonferroni post hoc test was used.
G.  Peptides
Animals received s.c. injections twice daily (8:00 am and 3:00 pm) with the GLP-1 analogue 
lira (Novo Nordisk) at a dose of 0.6 mg daily. Lira is a long-acting GLP-1 analogue due to 
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acylation and in the body is bound to albumin for a slow release; therefore, this compound 
was used for the in vivo experiments (52). To antagonize the GLP-1R we used GLP-1 (9-39) 
(EX-9) (53) (4 017 799.1000, H8740, Bachem) at a dose of 0.2 mg daily or PBS as control. 
Treatments were all started at day 10 after sensitization and continued until animals were 
humanely killed. Doses were chosen based on previous experiments (20).
ANP (A8208, Sigma-Aldrich) and exendin-4 (EX-4) (Caslo) for wire myography was 
dissolved in double-distilled H2O. EX-4 is a 39 AA peptide with 50% homology to GLP-1 (54) 
that is not influenced by variable protein binding. Therefore this compound was used for 
the in vitro experiments.
H.  Histopathology and Immunohistochemistry
Histopathology was carried out on the 4 groups: lira/PBS 12-h and lira/PBS 72-h (n = 32). The 
lungs were fixed by instillation of 4% paraformaldehyde through the trachea immediately 
after death. The lungs were removed from the cavity and placed in 4% paraformaldehyde 
for 24 to 48 hours. Next, the lungs were embedded in paraffin and 4-µM sections were cut 
and dried (60°C, 1 hour). Paraffin was removed with Histo-Clear (National Diagnostics, 
BioNordika) and sections were rehydrated in alcohol.
Sections stained with hematoxylin (Sigma-Aldrich) and eosin (Sigma-Aldrich) were used 
for histological investigation, and sections stained with periodic acid–Schiff (Sigma-Aldrich) 
were used for scoring of goblet cell metaplasia.
Antigen retrieval was achieved by boiling (microwave 20 minutes) in EDTA buffer pH 9 
(TA-125-PM4X, Thermo Fisher) for GLP-1R staining and citrate buffer pH 6 (TA-125-PM1X, 
Figure 1. Validation of KO mouse strain and optimization of COPD model. A, Insulin secre-
tion on GLP-1 stimulation by the pancreas using isolated pancreas perfusion. As opposed to 
the WT mice (black), the KO mice (green) do not respond to GLP-1. B, Immunohistochemical 
staining with GLP-1 R ab of pancreatic islets in (left) WT and (right) GLP-1R KO mice. 
Arrows point to pancreatic β cells in the islets of Langerhans but no immunoreaction in the 
GLP-1 R KO mouse. C, Comparison of responses to COPD-induction in BALB/c mice and 
C57BL/6JRj with and without sensitization with OVA pellets. D, Investigation of the duration 
and intensity of the response to COPD induction in C57BL/6JRj mice. Group 1 was measured 
from time 0 to 12 and 24 to 30 hours after the last LPS inhalation, and group 2 was measured 
from 12 to 24 hours.
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Thermo Fisher) for staining of pulmonary macrophages. UltraVision Quanto Mouse on 
Mouse Detection Systems (TL-060-QHDM, Thermo Fisher) was used following provided 
instructions. The primary antibodies used were GLP-1R ab clone 7F38-s (55,56,57) diluted 
1:50 and mannose receptor ab (58) diluted 1:12 000.
Semiquantitative histopathological scoring was carried out blinded based on the study 
by Zeldin et al (59). Scores were based on perivascular edema, perivascular/peribronchial 
acute inflammation, goblet cell metaplasia of the bronchioles, and macrophages/mononu-
clear cells in the alveolar spaces.
Statistical analysis of the inflammation scores was carried out using 1-way ANOVA 
followed by Bonferroni post hoc test comparing lira 12-h with PBS 12-h and lira 72-h with 
PBS 72-h.
I.  Inflammatory Markers
Blood was collected from the vena cava into EDTA-coated Eppendorf tubes before death 
and was directly centrifuged (1000  × g, 10  minutes, 4°C). Plasma was transferred into 
fresh Eppendorf tubes and was immediately placed on ice until storage at –20°C. Plasma 
concentrations of 10 different proinflammatory cytokines were measured using a multispot 
assay system (Cat. No.  K15048D, Meso Scale) according to the manufacturer’s instruc-
tion. The assay quantified interferon-γ, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10, 
IL-12p70, KC/GRO, and tumor necrosis factor (TNF)-α.
J.  Real-Time Reverse Transcriptase Quantitative Polymerase Chain Reaction
Total RNA was extracted using the Nucleo-Spin kit (740955, Macherey-Nagel) according to 
the manufacturer’s instructions. Quality of the extracted RNA was assessed from absorb-
ance measurements using a NanoDrop-1000 machine (Thermo Scientific). A total of 500 ng 
total RNA was used for complementary DNA (cDNA) synthesis with the iScript-cDNA Kit 
(1708891, BioRad). Real-time reverse transcriptase quantitative polymerase chain reac-
tion was performed on 12 ng cDNA with SybrGreen PCR mastermix (Life Technologies) 
using specific primers and run in a real-time PCR machine (Applied Biosystems). Gene 
expression levels were normalized to the reference gene Hprt1 (60) using the –∆Ct method. 
For simplicity, data are presented in the figures as fold-change values, which were calcu-
lated by the ∆∆Ct method. Target genes were ANP (nppa), ANPR-A (npr1), ANPR-C (npr3), 
endothelin-1 (end1), apelin (apln), and E-selectin (sele). Primer sequences are shown in 
Table 1. In addition to the COPD mice, we added 2 groups of healthy animals that were not 
exposed to COPD induction but received lira (0.6 mg daily) or PBS for 10 days. This group 
was considered “healthy” and used for comparison of messenger RNA expression levels in 
healthy and COPD mice. Statistics were carried out on ∆Ct values using 1-way ANOVA 
followed by Bonferroni post hoc test.
K.  Wire Myography
Mice were humanely killed by cervical dislocation and the entire lung was carefully removed 
and placed in Krebs Ringer bicarbonate solution (in mM: 118.3 NaCl, 4.7 KCl, 1.2 MgSO4, 
1.2 KH2PH4, 25 NaHCO3, 2.5 NaHCO2, 2.5 CaCl, and 10 glucose, pH 7.35-7.45) (61). The tra-
chea and main bronchi were isolated using a dissection microscope, and sections of 1 to 2 mm 
were cut from the main left and main right bronchus in close proximity to the bifurcation. 
The sections were mounted by threading them on 2 steel wires (40 µm diameter). Sections 
were placed in a wire myograph chamber (Danish Myo Technology) filled with 7 mL Krebs-
Ringer bicarbonate buffer (37°C and oxygenated with 95% O2 to 5% CO2 to maintain pH) 
and secured to 2 supporters. One of the supporters was attached to a micrometer, allowing 
control of ring circumference, and the other supporter was attached to a force transducer for 
measurements of isometric contraction. Tension was applied to the sections and the tissue 
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was left to equilibrate at resting tension for 1 hour before stretching to 3 mN for mice and 
5 mN for rats. Buffer was replaced every 30 minutes. Tissue responses (contraction) were 
measured in response to addition of potassium physiological saline solution buffer, rich in 
KCl (in mM: 74.7 NaCl, 60 KCl, 1.18 KH2PO4, 1.17 MgSO4*6H20, 14.9 NaHCO3, 0.0026 
EDTA, 1.6 CaCl *2H2O, 5.5 glucose). In the absence of proper contraction, the sections 
were further stretched in increments of 2 mN until a significant response to the potassium 
physiological saline solution was observed. In a pilot experiment, a dose-response curve to 
carbachol was established (1 × 10–10 to 1 × 10–3 M) to identify the concentration of carbachol 
resulting in a submaximal response approximately 80% of the maximum achievable. The 
desired submaximal contraction occurred at a concentration of 1 × 10–7 M, and this was 
used for subsequent studies testing the effects of either ANP or EX-4.
The bronchial rings were precontracted with carbachol (0.1 µM) and allowed to stabilize 
for 15 minutes before ANP or EX-4 was added in a cumulative fashion at 10-fold increases 
(0.001-1.0 µM) separated by 20 minutes between additions. At the end of each protocol, 
0.1 µM sodium nitroprusside (SNP; positive control) was added to relax the tissue com-
pletely and provide a standard (Rmax) to which the relaxation of each peptide was compared. 
The dilation by SNP was expressed as the percentage of preconstriction with carbachol. 
Wire myography was also carried out in bronchi of C57BL/6JRj COPD mice. Experiments 
were carried out 72 hours after the last LPS inhalation.
Statistics analyzing the effects of ANP and EX-4 at different concentrations were carried 
out by 1-way ANOVA followed by Bonferroni post hoc test comparing each concentration 
to 0.001  µM, which is considered as zero effect. Comparisons between sick and healthy 
animals were analyzed by 2-way ANOVA followed by Sidak post hoc test comparing the 
2 groups at each concentration.
2.  Results
A.  Validation of the Glucago-like Peptide-1 Receptor Knockout Strain
We generated a GLP-1R KO strain for this study and validated the strain functionally 
for the loss of GLP-1R activity by investigating GLP-1–induced potentiation of glucose-
stimulated insulin secretion from isolated perfused mouse pancreas. Stimulation with 
0.1 nM and 1.0 nM GLP-1 had no effects in GLP-1R KO mice but increased insulin secretion 
in WT littermates (Fig. 1A). Furthermore, we investigated the lack of GLP-1R expression 
by immunohistochemistry using a GLP-1R ab on pancreatic islets. As expected, there was 
no visible staining of the pancreatic β cells in GLP-1R KO mice, whereas WT littermates 
showed a normal staining pattern (Fig. 1B).
B.  Optimization of the Chronic Obstructive Pulmonary Disease Model
We found C57BL/6JRj to be more responsive to induction of COPD-like phenotype than 
BALB/c mice (Fig. 1C). Sensitization with an OVA pellet of C57BL/6JRj mice before OVA 
and LPS treatment resulted in a second peak in PenH values and prolonged the entire re-
sponse compared to the nonsensitized mice (Fig. 1C). Indeed, if mice were not sensitized, 
the obstruction was over in less than 12 hours compared to 30 hours in sensitized mice. 
PenH values reached a maximum between 10 to 12 hours after the last LPS inhalation and 
were back to normal (PenH < 1) after 24 hours (Fig. 1D). Having gained this insight, we 
measured PenH in all animals in subsequent experiments precisely 12, 14, and 16 hours 
after the last LPS inhalation, when lung disease was considered to be most severe.
C.  Endogenous Glucagon-Like Peptide-1 Is not Protective in Lung Disease
When measuring lung function in COPD mice, we found no significant difference between 
the EX-9- and PBS-treated groups regarding PenH at 12 hours after the last LPS inhalation, 
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whereas there was a significant decrease in PenH in the lira group compared to the PBS 
group (P < .01) (Fig. 2A).
We found no difference in PenH between the GLP-1R KO and WT littermates (Fig. 2B), 
supporting the lack of effect of endogenous GLP-1.
D.  Effect of Liraglutide on Histopathology and Inflammatory Markers in Chronic 
Obstructive Pulmonary Disease
The histopathological score was significantly decreased in the lira 12-h group compared to 
the PBS 12-h group (P < .05). In mice killed 72 hours after last LPS inhalation there was no 
difference between groups (Fig. 3A-3E). We found no difference with respect to the devel-
opment of emphysema between the groups receiving PBS or lira (Fig. 3F). Also, we found 
no difference in plasma concentrations of interferon-γ, IL-1β, IL2, IL-4, IL-5, IL-6, IL-10, 
IL-12p70, KC/GRO, and TNF-α between groups (PBS/lira 12-h and PBS/lira 72-h) (Fig. 2K). 
IL-1β, IL-4, and IL-12p70 were all less than the detection limit according to the quality con-
trol from the manufacturer.
E.  Gene Expression Analysis
Lung tissue was isolated from the 4 groups PBS/lira 12-h and PBS/lira 72-h from COPD 
mice and from healthy mice treated with lira or PBS but not subjected to the COPD model.
Transcripts of nppa were increased more than 10-fold in the lira 72-h group compared 
to the PBS 72-h group (P < .01) (Fig. 4A) and markedly increased when compared to the 
healthy lira group (P < .001). The expression of the ANP receptor  npr1 was increased 
16-fold in the PBS 12-h group compared to the lira 12-h group (P < .001) (Fig.  4B). 
Figure 2. Endogenous GLP-1 is not protective in COPD. Data are presented as time-effects 
plots from day 12 to 21 in the left panel. Right panel shows bar graphs at day 18, 12 hours 
after the last LPS inhalation. A, Study investigating the effect on PenH by antagonizing the 
GLP-1R with EX-9, n = 48. B, GLP-1R KO and WT, n = 30. Data are shown as means ± SEM. 
Statistics were carried out with 1-way ANOVA followed by Bonferroni post hoc test. **P < .01
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The clearance receptor for ANP, npr3, was upregulated by a factor of 2 in the 72-h PBS group 
compared to the 72-h PBS group (P < .05). Surprisingly, the healthy lira group expressed 
16-fold more npr3 than lira 12-h (P < .05; Fig. 4C). The expression of endothelin-1 (edn1) 
decreased in response to lira treatment (Fig. 4D). Levels were more than 17-fold lower in lira 
Figure 3. Effect of liraglutide on histopathology and inflammatory markers in COPD. A, Bar 
graph of histopathological score in the different groups. H&E staining showing B, perivas-
cular edema; C, perivascular/peribronchial acute inflammation; D, goblet cell metaplasia of 
the bronchioles; and E, macrophages/mononuclear cells in the alveolar spaces. F, Emphysema 
score. Examples of emphysema scored as G, mild; H, moderate; I, and severe. J, Healthy 
mouse lung for comparison. K, Measurements of proinflammatory cytokines in plasma 
from COPD mice. Comparisons were carried out between lira 12-h and PBS 12-h, lira 72 h 
and PBS 72 h. Data are shown as means ± SEM, n = 32. Statistics were analyzed by 1-way 
ANOVA followed by Bonferroni post hoc test. **P < .01.
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12-h vs PBS 12-h (P < .01) and 16-fold lower than the healthy lira group. There was no sig-
nificant difference between the lira and PBS groups regarding expression of apl and sele 
(Fig. 4D and 4F), but there was a significant increase in expression of sele in COPD mice at 
12 hours compared to the healthy group (P < .001).
Figure 4. Gene expression analysis. All genes were normalized to the housekeeping gene 
HPRT-1. A, ANP (nppa); B, ANPR-A (npr1); C, ANP clearance receptor, ANPR-C (npr3); 
and D, endothelin-1, ET-1 (edn1). E, Apelin (apl). F, E-selectin (sele). PBS healthy and lira 
healthy refer to animals treated for 10 days with liraglutide or PBS, but with no induction 
of COPD. Data are expressed as means ± SEM, n = 32. Statistics were analyzed using 1-way 
ANOVA followed by post hoc test comparing PBS and lira at 12 or 72 h *P < .05, **P < .01, 
***P < .001.
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F.  Atrial Natriuretic Peptide and Exendin-4 Both Exert Bronchodilating Effects on 
Isolated Mouse Bronchi
In healthy mice, significant relaxing effects of ANP were observed at 0.1  µM and 1  µM 
compared to 0.001 µM, which was considered to have no effect (P < .01) (Fig. 5A). At 1 µM 
ANP-mediated dilation was 12 ± 2% of Rmax. Ex-4 also showed bronchodilating effects 
(Fig. 5B), although to a lesser extent than ANP and with no significant difference between 
responses at increasing doses. The maximum response was achieved at 1 µM with 11 ± 3% 
of Rmax.
The maximal bronchodilating effect produced by ANP was 28.6 ± 8.9% of Rmax at 0.1 µM in 
bronchi from COPD mice, which was a 2-fold increase compared to bronchi from healthy mice 
(Fig. 5C). The COPD mice also showed a significantly greater response to EX-4, reaching a 
maximum at 0.1 µM with 17.7 ± 3.3% of Rmax corresponding to a 1.7-fold increase compared 
to the healthy mice (P < 0.5)(Fig. 5E). A few of the sections did not respond to the peptides, 
and these were excluded from the data set. Data including these “nonresponders” are shown 
in Fig. 6. Sections that did not respond to SNP were discarded from the experiment.
Figure 5. ANP and EX-4 both exerted bronchodilating effects on isolated bronchi of mice. 
Concentration-relaxation curves induced by ANP and EX-4 on bronchial smooth muscle 
tissue. Values are expressed relative to the maximal effect of SNP (0.1 mM), which was added 
at the end of the experiment. Data are shown as means ± SEM. A, Relaxation induced by 
ANP (0.001-1 mM) in healthy mice. B, Relaxation induced by EX-4 (0.001-1 mM) in healthy 
mice. C, The effect of ANP on tissue from COPD mice compared to healthy mice. D, The effect 
of EX-4 on COPD compared to healthy mice. Data from A and B were analyzed by 1-way 
ANOVA followed by Bonferroni post hoc test comparing each concentration to 0.001 mM, 
which was considered as zero effect. Data from C and D were analyzed by 2-way ANOVA 
followed by Sidak post hoc test comparing the responses of COPD and healthy mice at each 
concentration. *P < .05, **P < .01.
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3.  Discussion
Because asthma and COPD prevalence is increased in individuals with obesity and type 2 
diabetes (62, 63), and plasma GLP-1 concentrations are often decreased in these individuals 
(64, 65), we found it of interest to study whether endogenous GLP-1 could have protective 
functions in the pulmonary system. Previous studies have shown beneficial effects of GLP-1 
analogues in different models of lung disease. Viby et al used a mouse model of obstructive 
pulmonary disease and showed that treatment with lira and EX-4 was able to decrease mor-
tality rate and increase lung function by decreasing obstruction as measured by PenH (20). 
In a study of monocrotaline-induced pulmonary arterial hypertension, Lee and colleagues 
found that monocrotaline reduced endothelial nitric oxide (NO) synthase and thereby inhib-
ited NO production in blood vessels. Lira treatment reversed this reduction. Additionally, 
lira inhibited ROCK signaling and ET-1 levels (24). In 2 independent studies of GLP-1 on 
isolated segments of pulmonary vasculature and trachea from the rat, there were minor dil-
atory effects on the vasculature, and this effect was endothelial and NO dependent (21, 66).
However, endogenous GLP-1 did not have apparent protective effects in our model of 
COPD when GLP-1 signaling was attenuated acutely by administration of EX-9 nor by re-
ceptor deletion (GLP-1R KO mice). However, we were able to confirm that lira decreased 
PenH and thereby reduced bronchoconstriction.
There were, nevertheless, marked differences in PenH values between the experiments. 
These differences could be at least partly related to interstrain differences between the mice 
used in the antagonist studies, obtained from a commercial vendor, and the GLP-1R KO 
mice and WT littermates representing an inbred strain. Indeed, studies have shown great 
variability with both interstrain and intrastrain phenotypic variation caused by genetic 
heterogeneity (67, 68).
Figure 6. Direct effects of ANP and Ex-4 on smooth muscles of isolated mouse bronchi, 
including nonresponders. Concentration-relaxation curves induced by ANP and EX-4 on 
bronchial smooth muscle tissue. Relaxation values are expressed as a percentage of the re-
laxation seen with a maximally effective concentration of SNP (0.1 mM) added at the end of 
the experiment. Data are shown as means ± SEM. A, The effect of ANP on tissue from COPD 
compared to healthy mice. B, The effect of EX-4 on COPD mice compared to healthy mice. C, 
Example of myograph signals from tissue sections responding to ANP and D, not responding 
to ANP, but to SNP.
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For the present studies, we used a mouse model of COPD and evaluated the degree of 
disease by measuring lung function by PenH using unrestrained whole-body plethysmog-
raphy. In humans, pulmonary function is estimated by spirometry using the Tiffeneau index 
(forced expiratory volume in 1 s/forced vital capacity [FEV1/FVC] ratio), a method that is 
not applicable in animals. The most reliable measurement of airway resistance and bron-
chial obstruction is through forced oscillation. This invasive technique is time consuming 
and terminal for the animals and incompatible with repeated measurements. Unrestrained 
whole-body plethysmography has been widely used to assess bronchial responsiveness in 
mouse disease models. PenH, which is based on changes in breathing patterns, is a dimen-
sionless calculated measurement indicative of broncho-obstruction (49). This method has 
been criticized for being inadequate and an unreliable measurement of broncho-obstruction 
by some scientists (69-71), whereas others find it appropriate to use (49, 72-74), specifically 
in models of severe lung disease (75). Because we consider our model to be one of severe lung 
disease, we found it suitable for our studies. We found it more important that the animals 
were unrestrained and unanesthetized during our study period, thereby avoiding unneces-
sary stress that might be reflected in our results. Also, we were interested in longitudinal 
measurements that are not possible if using invasive measurements.
The decreased PenH values in the lira-treated group could to some extent reflect di-
rect effects on the muscle tissue surrounding the bronchi, causing relief of constriction but 
might also be due to an indirect effect through attenuation of the inflammatory response. 
Indeed, several studies have shown that GLP-1 also has anti-inflammatory effects (43) in 
lung disease (19, 41, 42, 76, 77). To some extent our data support these findings.
Our histopathological score revealed less histological inflammation in the lira-treated 
group 12 hours after last LPS inhalation compared to PBS. Similarly, in a study of bleomycin-
induced pulmonary fibrosis, Gou and colleagues found that lira decreased the number of 
macrophages and lymphocytes from bronchoalveolar lavage fluid. In that study, plasma 
concentrations of TNF-α, IL-6, and IL-1β were reduced with lira compared to placebo (19), 
whereas we were unable to detect any differences although the measured concentrations 
were within the detection and sensitivity range of the assay. On overexpression of GLP-1R 
in airway smooth muscle cells obtained from human biopsies, Sun and colleagues found 
decreased migration and proliferation as well as suppressed proinflammatory cytokines 
TNF-α, IL-4, and IL-1β (41). Whether these differences reflect interspecies variation, are a 
result of the supraphysiological expression of GLP-1R in the transfected cells, or linked to 
other differences between an in vivo and in vitro setup remains to be investigated further.
Although we did not find attenuation in levels of proinflammatory cytokines, our data 
confirm that lira treatment attenuated inflammation during the acute phase, 12 hours after 
the last LPS inhalation.
Part of our study aim was to investigate whether the beneficial effects of GLP-1 in lung 
disease were due to bronchodilatory effects elicited by stimulation of ANP secretion on 
GLP-1R activation. This hypothesis was inspired by the work of Kim et al from 2013 (12), 
showing that native GLP-1, EX-4, and lira all decreased blood pressure and increased natri-
uresis in hypertensive mice by mechanisms that were positively linked to increased plasma 
concentrations of ANP. Importantly, the beneficial effects were abolished in GLP-1R KO 
mice, suggesting that the ANP release was dependent on GLP-1R signaling. Later, the same 
authors carried out another study to investigate whether this translated to humans (78), 
but this did not appear to be the case.
Two other studies by another group arrived at a similar conclusion. Skov and colleagues 
found no increased levels of plasma proANP on native GLP-1 infusion in either healthy 
adult men or men with diabetes (79, 80). Following this study, the same group published an-
other paper supporting the existence of a gut-ANP axis. Here they found increased levels of 
plasma ANP on different kinds of meal intake, but this study does not narrow down whether 
this effect may be mediated by GLP-1 (81). The data on the role of GLP-1 and ANP secre-
tion in humans are, however, divergent and require further investigation because another 
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human study found that lira increased plasma concentrations of natriuretic peptides (ANP 
and BNP) after 12 weeks of treatment (82).
ANP is mainly secreted by the atrial cardiomyocytes but a few studies have reported se-
cretion from the lung (33, 34). Unfortunately, it was not technically feasible for us to measure 
secretion of ANP in the present experimental in vivo models because reliable low-volume 
assays with sufficient sensitivity are not currently available. Also, plasma levels of ANP do 
not reveal from which organ it is secreted. Instead, we performed qPCR on lung tissue from 
mice subjected to our COPD model and healthy controls. Here we found a 10-fold increase 
in nppa transcripts in the lira group 72 hours after the last LPS inhalation.
Besides the increase in transcripts of nppa in the lira-treated group, we found an even 
greater increase in the transcription of the receptor for ANP, nrp1. Unexpectedly, this was 
observed in the PBS-treated group. Also, we would expect to see the same difference be-
tween the 2 groups at 12 and 72 hours, which was not the case. We did, however, find a 
major improvement in Penh in the 12-h group treated with lira, and based on the lack 
of nppa expression our data do not support that the acute effect of GLP-1 is mediated by 
an upregulation of nppa. Interestingly, the expression of nrp3, an ANP clearance receptor, 
was increased in the lira 72-h group, possibly as a response to the increased transcription 
of nppa.
We also measured edn1 (ET-1). ET-1 is a peptide with bronchoconstricting properties, 
and elevated levels are found in patients with asthma and eosinophilic infiltrations as well 
as in patients with pulmonary hypertension (83). We found an 18-fold and 13-fold decrease 
in edn1 levels in the lira 12-h and 72-h group, respectively, compared to the PBS groups. 
These findings are supported by a study by Lee et al, who found a decrease in ET-1 levels 
on lira treatment in a rat model of pulmonary hypertension (24). In another study, it was 
found that ANP inhibited the expression of ET-1 in cardiac fibroblasts through a GATA-4–
dependent mechanism (84). Isono and colleagues found that ANP inhibited ET-1 activation 
of c-Jun NH2-terminal kinase in glomerular mesangial cells (85). Apparently, both lira and 
ANP have been found to inhibit the expression of ET-1. Our data do not reveal whether the 
decrease is due to a direct effect of lira or an indirect effect of the increased levels of ANP 
induced by lira, but edn1 upregulation could be the mediator of the reduced PenH in the 
acute phase.
Based on these findings we can conclude that ANP in the lung, at the transcriptional 
level, is increased on lira treatment. Moreover, this effect is more pronounced after reaching 
maximal constriction.
Bronchodilating effects of ANP are not novel. Several studies carried out in the 1990s 
showed that ANP has direct bronchodilatory effects on isolated bronchial tissue from guinea 
pig, rabbit, and cow (37, 40, 86) but the effect on mouse tissue has not been reported before. 
Consistent with the previous findings, we observed a bronchodilatory effect of ANP sur-
prisingly also an effect of GLP-1. However, the responses to EX-4 varied greatly between 
animals, with some responding robustly and others not responding at all (nonresponders: 
4/10). The responses to ANP also varied (nonresponders: 3/16) but not as much as with 
EX-4. Varying responses to ANP in bronchodilation were also observed by Hulks et al in 
asthmatic patients, among whom “some responded nicely and others not at all” (40).
Our gene expression data revealed that the expression of ANPR-A was upregulated 
under the disease state in the PBS-treated group. Therefore, we investigated whether this 
translated into increased sensitivity to ANP and EX-4 with regards to bronchodilatory 
effects. Indeed, response to ANP was 2.2-fold higher in COPD mice compared to healthy 
mice, and for EX-4 the response was 1.7-fold higher in COPD mice.
Taken together this shows that ANP and EX-4 both have direct bronchodilating effects, 
although the effect of ANP was more pronounced than that of EX-4. Moreover, these effects 
were significantly increased in sick animals, which is in line with the patterns of gene ex-
pression for the ANP receptor. Although this needs further investigation, our data could in-
dicate that the sick lung compensates by increasing its expression of ANPR-A, resulting in 
increased sensitivity to the potentially increased levels of ANP and increased bronchodilating 
effects of both peptides.
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4.  Conclusion
We were unable to show that endogenous GLP-1 plays a protective role in a mouse model of 
COPD, but exogenous doses of lira were indeed protective. Lira attenuated inflammation, 
but not the levels of proinflammatory cytokines. Expression of nppa was increased under 
disease states of the lung and was further increased on treatment with lira. ANP and to 
a lesser extent EX-4 have bronchodilatory properties that are more pronounced in COPD 
mice. Edn1 expression was decreased either as a direct consequence of lira or indirectly 
through the increase in ANP. The role of GLP-1 in lung disease still warrants more investi-
gation, including further studies of the link between GLP-1 and ANP. Our findings support 
studies of a potential role for GLP-1 analogues in the treatment for patients with acute ex-
acerbation of COPD.
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